Application Note
FACS: use at a diluton of 1/20 - 1/30. Cell permeabilization required. IHC-P: use at a diluton of 1/20 - 1/30. IHC-Fr: use at a diluton of 1/20 - 1/30. Optimal dilutions/concentrations should be determined by the end user.
Calculated MW
Positive Control
Positive tissue - Cell Lines: Drug-sensitive parental cell lines and their multidrugresistant derivativesNegative control antibody: Normal rat serum
Form
Liquid
Buffer
PBS, 1% BSA
Preservative
0.1% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4ºC.
Concentration
Batch dependent (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
Tissue / cell preparation; 2R120 cell line, derived by stepwise Doxorubicin exposure of the SW-1573 non-small cell lung carcinoma cell line.
Purification
IgG fraction
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
major vault protein , LRP , VAULT1
Cellular Localization
Cytoplasm
Background
This gene encodes the major component of the vault complex. Vaults are multi-subunit ribonucleoprotein structures that may be involved in nucleo-cytoplasmic transport. The encoded protein may play a role in multiple cellular processes by regulating the MAP kinase, JAK/STAT and phosphoinositide 3-kinase/Akt signaling pathways. The encoded protein also plays a role in multidrug resistance, and expression of this gene may be a prognostic marker for several types of cancer. Alternatively spliced transcript variants have been observed for this gene. [provided by RefSeq, May 2012]
Database
Research Area